PriceTargets.com logo

Adial Pharmaceuticals - ADIL Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 607.96%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$1.13 As of 12/17/2024 01:00 AM ET
▲ +0.03 (2.73%)

This chart shows the closing price for ADIL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adial Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADIL

Analyst Price Target is $8.00
▲ +607.96% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Adial Pharmaceuticals in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 607.96% upside from the last price of $1.13.

This chart shows the closing price for ADIL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 2 polled investment analysts is to buy (strong buy) stock in Adial Pharmaceuticals. This rating has held steady since September 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024RODMAN&RENSHAWUpgradeStrong-Buy
11/14/2024Rodman & RenshawInitiated CoverageBuy$8.00
10/3/2022Brookline Capital ManagementReiterated RatingBuy
8/17/2022Maxim GroupDowngradeBuy ➝ Hold
7/21/2022Maxim GroupLower Target$125.00 ➝ $75.00
11/30/2021Litchfield Hills ResearchReiterated RatingBuy
10/13/2021Brookline Capital AcquisitionInitiated CoverageBuy$300.00
10/13/2021Brookline Capital ManagementReiterated RatingBuy$300.00
8/26/2021Litchfield Hills ResearchBoost TargetBuy$125.00 ➝ $375.00
8/20/2021Maxim GroupReiterated RatingBuy$125.00
6/29/2021Litchfield Hills ResearchInitiated CoverageBuy$125.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/19/2024
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Adial Pharmaceuticals logo
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Read More

Today's Range

Now: $1.13
Low: $1.07
High: $1.13

50 Day Range

MA: $1.04
Low: $0.94
High: $1.23

52 Week Range

Now: $1.13
Low: $0.77
High: $4.17

Volume

145,099 shs

Average Volume

2,463,541 shs

Market Capitalization

$7.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Adial Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Adial Pharmaceuticals in the last twelve months: Rodman & Renshaw, and RODMAN&RENSHAW.
View the latest analyst ratings for ADIL.

What is the current price target for Adial Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Adial Pharmaceuticals in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 608.0%. Rodman & Renshaw has the highest price target set, predicting ADIL will reach $8.00 in the next twelve months. Rodman & Renshaw has the lowest price target set, forecasting a price of $8.00 for Adial Pharmaceuticals in the next year.
View the latest price targets for ADIL.

What is the current consensus analyst rating for Adial Pharmaceuticals?

Adial Pharmaceuticals currently has 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for ADIL.

What other companies compete with Adial Pharmaceuticals?

Other companies that are similar to Adial Pharmaceuticals include Daré Bioscience, DURECT, Longeveron, Lipocine and Natural Alternatives International. Learn More about companies similar to Adial Pharmaceuticals.

How do I contact Adial Pharmaceuticals' investor relations team?

Adial Pharmaceuticals' physical mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company's listed phone number is (434) 422-9800 and its investor relations email address is [email protected]. The official website for Adial Pharmaceuticals is www.adialpharma.com. Learn More about contacing Adial Pharmaceuticals investor relations.